Related Experiment Video
Updated: Aug 14, 2026

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis
Published on: July 18, 2017
Nephrotoxicity of intravenous colistin: a prospective evaluation
Matthew E Falagas1, Konstantinos N Fragoulis, Sofia K Kasiakou
1Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece. matthew.falagas@tufts.edu
Abstract:
Twenty-one patients who received intravenous colistimethate sodium (CMS) for at least 7 days for the treatment of multidrug-resistant Gram-negative bacterial infections were included in a prospective cohort study at 'Henry Dunant' Hospital in Athens, Greece. The mean (+/- standard deviation) and median daily doses, cumulative doses and duration of treatment of intravenous CMS were, respectively, 5.5 (+/- 1.9) and 6 million IU, 90.2 (+/- 52.0) and 72 million IU, and 17.7 (+/- 11.7) and 15 days (range 7-54 days). Three patients (14.3%) developed nephrotoxicity during treatment with CMS. The cumulative dose of administered CMS was statistically correlated with the difference in values of serum creatinine between the end and start of CMS treatment (r = 0.6, P = 0.004 by Spearman's test).
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Cardiac Catheterization I: Pre-Procedure Overview
Acute Pyelonephritis II: Diagnostic Studies and Management
Imaging Studies VII: Vascular Imaging
